Skip to main content

Table 3 Cox-Regression analysis for disease free survival and overall survival in patients with clinical stage III/N2 NSCLC

From: Impact of fibrinogen levels and modified Glasgow prognostic score on survival of stage III/N2 non-small cell lung cancer patients treated with neoadjuvant therapy and radical resection

Cox-Regression

Disease free survival

Overall survival

HR

95% CI

p-value

HR

95% CI

p-value

Difference in fibrinogena

0.996

0.991–1.001

0.136

0.994

0.989–0.999

0.025

Decrease in mGPSb

0.501

0.125–2.004

0.328

0.414

0.088–1.949

0.265

N2 downstaging

0.796

0.297–2.130

0.649

0.563

0.194–1.636

0.291

CHT/RT vs CHT

0.170

0.033–0.876

0.034

0.099

0.014–0.679

0.019

cStage

0.436

0.102–1.857

0.262

0.372

0.077–1.800

0.219

Histology (ADC vs other)

0.916

0.306–2.737

0.875

0.621

0.200–1.929

0.410

Age (continuously)

0.998

0.940–1.061

0.955

1.052

0.971–1.141

0.215

  1. mGPS Modified glasgow prognostic score, CHT/RT Chemoradiotherapy, CHT Chemotherapy, ADC Adenocarcinoma
  2. a,bData were available for fibrinogen in 34 patients (40.5%) and mGPS in 45 patients (53.7%) at time of diagnosis and prior surgery
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us